Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433039 | 0.91 | TP53 (0.44) | MAPTHPGDMEN1KMT2A | |
| SCHEMBL13552273 | 0.90 | MAPT (0.56) | MAPTHPGDMEN1KMT2ANPSR1 | |
| SCHEMBL1259194 | 0.83 | CYP19A1 (0.42) | MAPTHPGDMEN1KMT2ANPSR1 | |
| SCHEMBL1259189 | 0.83 | CYP19A1 (0.42) | MAPTHPGDMEN1KMT2ANPSR1 | |
| SCHEMBL8138421 | 0.82 | MAPT (0.50) | MAPTHPGDMEN1KMT2ANPSR1 | |
| SCHEMBL3519645 | 0.82 | KDM4E (0.62) | MAPTHPGD | |
| SCHEMBL77732 | 0.82 | MEN1 (0.63) | MAPTHPGDMEN1KMT2ANPSR1 | |
| SCHEMBL5142723 | 0.81 | MAPK1 (0.47) | MAPTHPGDMEN1KMT2ANPSR1 | |
| SCHEMBL2414235 | 0.81 | MAPT (0.49) | MAPTHPGDCYP2C9 | |
| SCHEMBL3921874 | 0.81 | MAPT (0.67) | MAPTHPGDMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-1568700-B1 | S-triazine derivatives containing at least two silated p-aminobenzalmalonate groups, sunscreen compositions containing these derivatives as well as the use of the derivatives | OREAL (FR) | 2007-08-08 | — | — | EP | disclosed |
| US-6517742-B1 | 2-(butyl 4'-ylaminobenzoate)-4,6-bis((1,3,3,3-tetramethyl-1 -((trimethylsilyl)oxy)disiloxanyl)propyl-3-ylamino)-s-triazine; s-triazine derivatives substituted by at least one silicone group; from cyanuric chloride | L'OREAL (FR) | 2003-02-11 | — | — | US | disclosed |
| US-5928630-A | PROTECT AGAINST SOLAR RADIATION; ABSORB BOTH ULTRAVIOLET A AND B RADIATION | Societe L' Oreal S.A. (FR) | 1999-07-27 | — | — | US | disclosed |
| US-5849909-A | Benzalmalonatae/phenylcyanoacrylate-substituted S-triazine compounds | SOCIETE L'OREAL S.A. (FR) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | MAPT 121/4885HPGD 549/4885MEN1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.